During the last session, Omega Therapeutics Inc (NASDAQ:OMGA)’s traded shares were 0.32 million, with the beta value of the company hitting 1.68. The 52-week high for the OMGA share is $6.30, that puts it down -549.48 from that peak though still a striking 22.68% gain since the share price plummeted to a 52-week low of $0.75. The company’s market capitalization is $53.65M, and the average intraday trading volume over the past 10 days was 0.26 million shares, and the average trade volume was 306.44K shares over the past three months.
Omega Therapeutics Inc (OMGA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. OMGA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Omega Therapeutics Inc (NASDAQ:OMGA) trade information
Omega Therapeutics Inc (OMGA) registered a -0.53% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.53% in intraday trading to $0.97, hitting a weekly high. The stock’s 5-day price performance is 0.63%, and it has moved by -9.44% in 30 days. Based on these gigs, the overall price performance for the year is -63.98%. The short interest in Omega Therapeutics Inc (NASDAQ:OMGA) is 6.36 million shares and it means that shorts have 16.34 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 89.22% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $11 respectively. As a result, OMGA is trading at a discount of -1034.02% off the target high and -621.65% off the low.
Omega Therapeutics Inc (OMGA) estimates and forecasts
Statistics show that Omega Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Omega Therapeutics Inc (OMGA) shares have gone down -52.27% during the last six months, with a year-to-date growth rate more than the industry average at 33.89% against 17.10. In the rating firms’ projections, revenue will increase 177.66% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.2M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 866.17k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 989k and 2.36M respectively. In this case, analysts expect current quarter sales to grow by 21.40% and then drop by -63.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -48.08%. While earnings are projected to return 34.07% in 2024.
OMGA Dividends
Omega Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Omega Therapeutics Inc (NASDAQ:OMGA)’s Major holders
Omega Therapeutics Inc insiders own 1.62% of total outstanding shares while institutional holders control 90.43%, with the float percentage being 91.92%. FLAGSHIP PIONEERING INC. is the largest shareholder of the company, while 70.0 institutions own stock in it. As of 2024-06-30, the company held over 29.23 million shares (or 52.9924% of all shares), a total value of $60.5 million in shares.
The next largest institutional holding, with 6.24 million shares, is of FMR LLC’s that is approximately 11.3181% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.92 million.
Also, the Mutual Funds coming in first place with the largest holdings of Omega Therapeutics Inc (OMGA) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . Data provided on Oct 31, 2024 indicates that Fidelity Growth Company Fund owns about 2.01 shares. This amounts to just over 3.63 percent of the company’s overall shares, with a $1.95 million market value. The same data shows that the other fund manager holds slightly less at 779.1, or about 1.41% of the stock, which is worth about $0.75 million.
